期刊
ANNUAL REVIEW OF MEDICINE, VOL 70
卷 70, 期 -, 页码 521-547出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-112017-091045
关键词
chimeric antigen receptor T cells; immunotherapy; monoclonal antibodies; multiple myeloma; novel agents
资金
- NATIONAL CANCER INSTITUTE [R01CA184464, R01CA194264] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA194264, P50 CA142509, R01 CA184464] Funding Source: Medline
Multiple myeloma is diagnosed in over 100,000 patients each year worldwide, has an increasing incidence and prevalence in many regions, and follows a relapsing course, making it a significant and growing healthcare challenge. Recent basic, translational, and clinical studies have expanded our therapeutic armamentarium, which now consists of alkylating agents, corticosteroids, deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors. New drugs in these categories, and additional agents, including both small and large molecules, as well as cellular therapies, are under development that promise to further expand our capabilities and bring us closer to the cure of this plasma cell dyscrasia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据